394 related articles for article (PubMed ID: 25740997)
41. A Highly Pathogenic Avian H7N9 Influenza Virus Isolated from A Human Is Lethal in Some Ferrets Infected via Respiratory Droplets.
Imai M; Watanabe T; Kiso M; Nakajima N; Yamayoshi S; Iwatsuki-Horimoto K; Hatta M; Yamada S; Ito M; Sakai-Tagawa Y; Shirakura M; Takashita E; Fujisaki S; McBride R; Thompson AJ; Takahashi K; Maemura T; Mitake H; Chiba S; Zhong G; Fan S; Oishi K; Yasuhara A; Takada K; Nakao T; Fukuyama S; Yamashita M; Lopes TJS; Neumann G; Odagiri T; Watanabe S; Shu Y; Paulson JC; Hasegawa H; Kawaoka Y
Cell Host Microbe; 2017 Nov; 22(5):615-626.e8. PubMed ID: 29056430
[TBL] [Abstract][Full Text] [Related]
42. Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus.
Pizzorno A; Abed Y; Bouhy X; Beaulieu E; Mallett C; Russell R; Boivin G
Antimicrob Agents Chemother; 2012 Mar; 56(3):1208-14. PubMed ID: 22203589
[TBL] [Abstract][Full Text] [Related]
43. Characterization of Influenza B Virus Variants with Reduced Neuraminidase Inhibitor Susceptibility.
Farrukee R; Zarebski AE; McCaw JM; Bloom JD; Reading PC; Hurt AC
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30201817
[TBL] [Abstract][Full Text] [Related]
44. An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza A virus subtype H7N9 and protects mice from lethality.
Marjuki H; Mishin VP; Chesnokov AP; De La Cruz JA; Fry AM; Villanueva J; Gubareva LV
J Infect Dis; 2014 Aug; 210(3):435-40. PubMed ID: 24569063
[TBL] [Abstract][Full Text] [Related]
45. Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus.
Kiso M; Ozawa M; Le MT; Imai H; Takahashi K; Kakugawa S; Noda T; Horimoto T; Kawaoka Y
J Virol; 2011 May; 85(10):4667-72. PubMed ID: 21367898
[TBL] [Abstract][Full Text] [Related]
46. Development of a quadruple qRT-PCR assay for simultaneous identification of highly and low pathogenic H7N9 avian influenza viruses and characterization against oseltamivir resistance.
Yang Y; Li S; Wong G; Ma S; Xu Z; Zhao X; Li H; Xu W; Zheng H; Lin J; Zhao Q; Liu W; Liu Y; Gao GF; Bi Y
BMC Infect Dis; 2018 Aug; 18(1):406. PubMed ID: 30111290
[TBL] [Abstract][Full Text] [Related]
47. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo.
Yen HL; Ilyushina NA; Salomon R; Hoffmann E; Webster RG; Govorkova EA
J Virol; 2007 Nov; 81(22):12418-26. PubMed ID: 17855542
[TBL] [Abstract][Full Text] [Related]
48. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo.
Carr J; Ives J; Kelly L; Lambkin R; Oxford J; Mendel D; Tai L; Roberts N
Antiviral Res; 2002 May; 54(2):79-88. PubMed ID: 12062393
[TBL] [Abstract][Full Text] [Related]
49. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets.
Herlocher ML; Truscon R; Elias S; Yen HL; Roberts NA; Ohmit SE; Monto AS
J Infect Dis; 2004 Nov; 190(9):1627-30. PubMed ID: 15478068
[TBL] [Abstract][Full Text] [Related]
50. Application of a seven-target pyrosequencing assay to improve the detection of neuraminidase inhibitor-resistant Influenza A(H3N2) viruses.
Tamura D; Okomo-Adhiambo M; Mishin VP; Guo Z; Xu X; Villanueva J; Fry AM; Stevens J; Gubareva LV
Antimicrob Agents Chemother; 2015 Apr; 59(4):2374-9. PubMed ID: 25645846
[TBL] [Abstract][Full Text] [Related]
51. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors.
Mishin VP; Hayden FG; Gubareva LV
Antimicrob Agents Chemother; 2005 Nov; 49(11):4515-20. PubMed ID: 16251290
[TBL] [Abstract][Full Text] [Related]
52. The evolution and characterization of influenza A(H7N9) virus under the selective pressure of peramivir.
Ge Y; Chi Y; Min X; Zhao K; Wu B; Wu T; Zhu X; Shi Z; Zhu F; Cui L
Virology; 2019 Oct; 536():58-67. PubMed ID: 31400550
[TBL] [Abstract][Full Text] [Related]
53. Reduction of Neuraminidase Activity Exacerbates Disease in 2009 Pandemic Influenza Virus-Infected Mice.
Ranadheera C; Hagan MW; Leung A; Collignon B; Cutts T; Theriault S; Embury-Hyatt C; Kobasa D
J Virol; 2016 Nov; 90(21):9931-9941. PubMed ID: 27558428
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil.
Taniguchi K; Ando Y; Nobori H; Toba S; Noshi T; Kobayashi M; Kawai M; Yoshida R; Sato A; Shishido T; Naito A; Matsuno K; Okamatsu M; Sakoda Y; Kida H
Sci Rep; 2019 Mar; 9(1):3466. PubMed ID: 30837531
[TBL] [Abstract][Full Text] [Related]
55. Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Model.
Koszalka P; George A; Dhanasekaran V; Hurt AC; Subbarao K
mBio; 2022 Aug; 13(4):e0105622. PubMed ID: 35938724
[TBL] [Abstract][Full Text] [Related]
56. Comparable fitness and transmissibility between oseltamivir-resistant pandemic 2009 and seasonal H1N1 influenza viruses with the H275Y neuraminidase mutation.
Wong DD; Choy KT; Chan RW; Sia SF; Chiu HP; Cheung PP; Chan MC; Peiris JS; Yen HL
J Virol; 2012 Oct; 86(19):10558-70. PubMed ID: 22811535
[TBL] [Abstract][Full Text] [Related]
57. Characterization of H7N9 influenza A viruses isolated from humans.
Watanabe T; Kiso M; Fukuyama S; Nakajima N; Imai M; Yamada S; Murakami S; Yamayoshi S; Iwatsuki-Horimoto K; Sakoda Y; Takashita E; McBride R; Noda T; Hatta M; Imai H; Zhao D; Kishida N; Shirakura M; de Vries RP; Shichinohe S; Okamatsu M; Tamura T; Tomita Y; Fujimoto N; Goto K; Katsura H; Kawakami E; Ishikawa I; Watanabe S; Ito M; Sakai-Tagawa Y; Sugita Y; Uraki R; Yamaji R; Eisfeld AJ; Zhong G; Fan S; Ping J; Maher EA; Hanson A; Uchida Y; Saito T; Ozawa M; Neumann G; Kida H; Odagiri T; Paulson JC; Hasegawa H; Tashiro M; Kawaoka Y
Nature; 2013 Sep; 501(7468):551-5. PubMed ID: 23842494
[TBL] [Abstract][Full Text] [Related]
58. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation.
Hurt AC; Holien JK; Parker M; Kelso A; Barr IG
J Virol; 2009 Oct; 83(20):10366-73. PubMed ID: 19641000
[TBL] [Abstract][Full Text] [Related]
59. Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors.
Baek YH; Song MS; Lee EY; Kim YI; Kim EH; Park SJ; Park KJ; Kwon HI; Pascua PN; Lim GJ; Kim S; Yoon SW; Kim MH; Webby RJ; Choi YK
J Virol; 2015 Jan; 89(1):287-99. PubMed ID: 25320319
[TBL] [Abstract][Full Text] [Related]
60. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.
Ives JA; Carr JA; Mendel DB; Tai CY; Lambkin R; Kelly L; Oxford JS; Hayden FG; Roberts NA
Antiviral Res; 2002 Aug; 55(2):307-17. PubMed ID: 12103431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
